Looks to have merit but presumably expensive to get unless listed on PBS.
Bristol Myers Squibb Announces Positive Phase 3 Trial Results for Sotyktu in Treating Psoriatic Arthritis
Bristol Myers Squibb Company has announced positive results from the pivotal Phase 3 POETYK PsA-1 trial evaluating the efficacy and safety of Sotyktu in adults with psoriatic arthritis. The study demonstrated that significantly more patients treated with Sotyktu achieved improvements in joint and skin symptoms, as well as in measures of disease activity and quality of life by Week 16. Additionally, new data from the POETYK PsA-2 trial indicated that clinical responses continued to improve and outcomes were maintained through Week 52. Sotyktu was well tolerated and demonstrated a safety profile consistent with previous studies. The results from the POETYK PsA-1 trial are being presented as a late-breaking abstract at the European Alliance of Associations for Rheumatology Congress in Barcelona, Spain, from June 11-14, 2025.Disclaimer: This news brief was created by Public Technologies using generative artificial intelligence. While PUBT strives to provide accurate and timely informati
The chart is obviously wrong presumably an AI glitch. It seems that Motley Fool is not even cursorily checking what they put out there in their name. Peter Cavanagh
Prediction: Palantir's Stock Will Make a Huge Move After May 5
Palantir's stock moved at a double-digit rate in each of the last four earnings reports.The stock has a premium valuation that will hamper any upward movement.$Palantir Technologies$ may be one of the most polarizing AI stocks on the market. Some swear by it, and others wouldn't touch it with a 10-foot pole. I'm usually in the 10-foot pole camp, but I would happily change my stance if the stock returned to a reasonable level.After the most recent round of sell-offs, Palantir stock is around 25%